Ticker
AKYA

Price
13.92
Stock movement up
+0.68 (5.14%)
Company name
Akoya Biosciences Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Medical Instruments & Supplies
Market cap
523.25M
Ent value
509.89M
Price/Sales
32.38
Price/Book
4.91
Div yield
-
Div growth
-
Growth years
-
FCF payout
-2.61%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-18.41%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AKYA does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales32.38
Price to Book4.91
EV to Sales31.56

FINANCIALS

Per share

Loading...
Per share data
Current share count37.59M
EPS (TTM)-0.94
FCF per share (TTM)-1.47

Income statement

Loading...
Income statement data
Revenue (TTM)16.16M
Gross profit (TTM)-20.43M
Operating income (TTM)-33.90M
Net income (TTM)-34.85M
EPS (TTM)-0.94
EPS (1y forward)-1.14

Margins

Loading...
Margins data
Gross margin (TTM)-126.46%
Operating margin (TTM)-209.78%
Profit margin (TTM)-215.70%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash93.94M
Net receivables11.31M
Total current assets126.47M
Goodwill18.26M
Intangible assets20.96M
Property, plant and equipment0.00
Total assets187.13M
Accounts payable11.52M
Short/Current long term debt43.72M
Total current liabilities31.74M
Total liabilities80.58M
Shareholder's equity106.55M
Net tangible assets67.33M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-49.60M
Capital expenditures (TTM)5.33M
Free cash flow (TTM)-54.92M
Dividends paid (TTM)1.44M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-32.71%
Return on Assets-18.63%
Return on Invested Capital-31.76%
Cash Return on Invested Capital-50.05%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open13.27
Daily high14.06
Daily low13.03
Daily Volume130K
All-time high26.05
1y analyst estimate18.75
Beta-
EPS (TTM)-0.94
Dividend per share-
Ex-div date-
Next earnings date7 Nov 2022

Downside potential

Loading...
Downside potential data
AKYAS&P500
Current price drop from All-time high-46.56%-12.18%
Highest price drop-67.83%-56.47%
Date of highest drop9 May 20229 Mar 2009
Avg drop from high-45.24%-11.38%
Avg time to new high345 days12 days
Max time to new high344 days1805 days
COMPANY DETAILS
AKYA (Akoya Biosciences Inc) company logo
Marketcap
523.25M
Marketcap category
Small-cap
Description
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Employees
319
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming inv...
August 31, 2022
In this article, we discuss 10 rebounding small cap stocks to buy now. If you want to see the top stocks in this category, check out 5 Rebounding Small-Cap Stocks to Buy Now. Carter Worth, the CEO of ...
August 11, 2022
Thank you for standing by, and welcome to the Akoya Biosciences second quarter 2022 earnings conference call. On the call today, we have Brian McKelligon, chief executive officer; and Joe Driscoll, c...
August 9, 2022
Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 8, 2022
Q2 2022 revenue $17.9 million, 37% y/y growthRaising FY 2022 revenue guidance range to $71-74 million MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Ako...
August 8, 2022
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming inve...
July 27, 2022
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the sec...
July 12, 2022
Akoya Biosciences AKYA is a life sciences company that provides spatial biology solutions focused on transforming discovery and clinical research. In this daily bar chart of AKYA, below, we can see b...
July 1, 2022
If you want to know who really controls Akoya Biosciences, Inc. ( NASDAQ:AKYA ), then you'll have to look at the makeup...
June 29, 2022
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted on...
June 28, 2022
Next page